Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger B Cohen

Showing results (101-110 of 208) with videos related to

Pageof 21
Sort By:
Clinical Lung Cancer|April 8, 2022
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and PemetrexedChristine A Ciunci, Jacob B Reibel, Tracey L Evans, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2014
Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapyJ Nicholas Lukens, Alexander Lin, Victoria Gamerman, et al.
Head & Neck|February 19, 2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer, Eric M Horwitz, Jonathan Cheng, et al.
The Laryngoscope|May 2, 2023
Functional Outcomes in Patients with Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Treated with Trimodality TherapyJoseph S Lu, Austin C Cao, David Shimunov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancerEric B Haura, Alejandro D Ricart, Timothy G Larson, et al.
BMC Cancer|October 12, 2021
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemicVivek Nimgaonkar, Charu Aggarwal, Abigail T Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
JAMA Oncology|July 12, 2019
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 TrialJoshua M Bauml, Rosemarie Mick, Christine Ciunci, et al.
Cancer|September 14, 2012
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanomaSapna P Patel, Alexander J Lazar, Nicholas E Papadopoulos, et al.
Head & Neck|September 9, 2014
HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgeryJohn M Kaczmar, Kay See Tan, Daniel F Heitjan, et al.
Pageof 21

Showing results (101-110 of 208) with videos related to

Sort By:
Pageof 21
Clinical Lung Cancer|April 8, 2022
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and PemetrexedChristine A Ciunci, Jacob B Reibel, Tracey L Evans, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2014
Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapyJ Nicholas Lukens, Alexander Lin, Victoria Gamerman, et al.
Head & Neck|February 19, 2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer, Eric M Horwitz, Jonathan Cheng, et al.
The Laryngoscope|May 2, 2023
Functional Outcomes in Patients with Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Treated with Trimodality TherapyJoseph S Lu, Austin C Cao, David Shimunov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancerEric B Haura, Alejandro D Ricart, Timothy G Larson, et al.
BMC Cancer|October 12, 2021
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemicVivek Nimgaonkar, Charu Aggarwal, Abigail T Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
JAMA Oncology|July 12, 2019
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 TrialJoshua M Bauml, Rosemarie Mick, Christine Ciunci, et al.
Cancer|September 14, 2012
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanomaSapna P Patel, Alexander J Lazar, Nicholas E Papadopoulos, et al.
Head & Neck|September 9, 2014
HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgeryJohn M Kaczmar, Kay See Tan, Daniel F Heitjan, et al.
Pageof 21